Drug intelligence / Profile preview

iscartrelvir

Development stage: Phase 3
Lead developer: Westlake University
Modality: Small Molecules
Administration: Oral

Overview

Iscartrelvir is an investigational oral small‑molecule antiviral that acts as a noncovalent inhibitor of the SARS‑CoV‑2 main protease (3C-like protease, 3CLpro), thereby blocking viral polyprotein processing and replication. Structurally, it is a brominated isoquinolinecarboxamide derivative (C24H24BrN5O4) identified through structure-based design as a potent, selective 3CLpro inhibitor against SARS‑CoV‑2, including variants of concern.[10][12] Iscartrelvir is being developed as a direct-acting antiviral therapy for COVID‑19 and potentially other coronavirus infections.

Other names: iscartrelvir

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on iscartrelvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iscartrelvir.

Explore the full profile